Latest news with #SCRI
NDTV
a day ago
- Business
- NDTV
Investment, Port Digitisation Discussed In India-Japan Meet On Maritime Ties
Investment, port digitisation and employment of Indian seafarers by Japan were among the topics discussed by Union Minister of Ports, Shipping & Waterways Sarbananda Sonowal in a bilateral meeting with Terada Yoshimichi, Japan's Vice Minister for International Affairs, and the Ministry of Land, Infrastructure, Transport & Tourism (MLITT). Monday's meeting between the two countries also included discussions on green port initiatives, increase in research and development cooperation, upskilling human resources, and using sustainable technologies, disaster-resilient infrastructure, and enhanced connectivity to enable Andaman and Nicobar and Lakswadeep islands to be converted into Smart Islands. Acknowledging the rich expertise of Japan in developing island territories, Mr Sonowal said, "Japan's expertise in this area is highly valued. We see scope for joint work in the Andaman & Nicobar and Lakshadweep islands, particularly in deploying renewable energy, smart mobility systems, and digital infrastructure. These initiatives will further our shared commitment to ecological conservation and regional maritime security." The meeting also discussed about increasing partnership between Indian and Japanese shipyards, including greenfield investment, such as Imabari Shipbuilding in Andhra Pradesh. Opportunities for co-development of ports and maritime industrial clusters were also gauged for mutual cooperation. Mr Sonowal expressed India's interest in leading Japanese shipbuilding companies such as Imabari Shipbuilding, JMUC, Kanagawa Dockyard, and Mitsubishi Heavy Industries to explore joint ventures and collaborative arrangements with Indian yards. "Japan's expertise in shipbuilding and ship repair is well recognised, and I see great scope for collaboration in this area. We also invite Japan's Big Three maritime companies-NYK Line, MOL, and K Line-to explore joint ventures and investment opportunities in India's growing maritime sector. With our strong bilateral relationship, India's growing maritime industry present a unique opportunity for Japanese shipyards to invest in India in shipbuilding. Collaboration on port digitisation and green port initiatives will further strengthen the resilience and sustainability of our maritime logistics network," said Mr Sonowal. Speaking on the occasion, Mr Sonowal said, "Relations between India and Japan have a long history rooted in spiritual affinity and strong cultural and civilisational ties. Our collaboration under the Quad framework and the India-Japan-Australia Supply Chain Resilience Initiative (SCRI) reflects our shared commitment to strengthening regional maritime security and economic integration. India appreciates Japan's leadership in key initiatives such as the International Solar Alliance (ISA), Coalition for Disaster Resilient Infrastructure (CDRI), and the Leadership Group for Industry Transition (LeadIT). As India moves ahead to transform its maritime sector under the visionary leadership of Prime Minister Narendra Modi, India is advancing port infrastructure, green shipping, shipbuilding and digitalisation under 'Maritime India Vision 2030' and 'Maritime Amrit Kaal Vision 2047'. India seeks Japan's participation in these transformative initiatives." Mr Yoshimichi expressed that India and Japan have very intimate relationship. Japan has been engaged in railway infrastructure development with India but now it is "very interested in maritime sector", he said. Prospects of mutual collaboration in shipbuilding and training of seafarers were discussed and considered positively. Emphasising the need to deepen bilateral ties in maritime training and development, as well as cooperation in research and development, both sides agreed to further strengthen collaboration in the maritime sector, especially on sustainable maritime technologies and next-generation ship design. Mr Sonowal evinced India's interest for a Memorandum of Understanding for a framework to avail promising avenues for collaboration with Cochin Shipyard Limited (CSL), Indian universities and public agencies.
Business Wire
6 days ago
- Business
- Business Wire
Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies
NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced a strategic alliance with AbbVie. The alliance aims to accelerate the development of innovative therapies for patients with cancer through collaborative scientific engagement and operational synergies to enhance the delivery of clinical trials. "By combining SCRI's scientific and operational expertise in conducting clinical trials in the community with AbbVie's innovative drug development approach, we can further strengthen our mission to advance novel therapies for patients," said Dee Anna Smith, Chief Executive Officer, SCRI. "Working together, we can expedite the development of more treatment options and transform clinical trial delivery, providing greater access to cutting-edge therapies for patients close to home.' SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Through the alliance, SCRI and AbbVie will enhance scientific connectivity, enabling collaboration with SCRI's physician leadership and contract research organization, SCRI Development Innovations, to drive clinical development. 'We are encouraged about the opportunity to establish a strategic scientific alliance with SCRI as we work together on initiatives aimed to address high unmet needs for patients battling cancer," said Svetlana Kobina, MD., PhD., Vice President of AbbVie Oncology, Global Medical Affairs. "Through close collaboration with SCRI and its community sites, we hope to gain a more comprehensive understanding of the treatment paths and health needs of patients living with cancer to provide tailored, patient-centered scientific solutions. This partnership enables us to delve deeper into the challenges faced by medical oncologists, hematologists, patients and caregivers to help us design clinical studies that more accurately represent all patient communities.' The collaboration will leverage SCRI's advanced research operational capabilities through its Accelero model, which maximizes site contributions, optimizes site activation timelines, and synchronizes end-to-end clinical research management. The Accelero model utilizes SCRI's robust Personalized Medicine program, including centralized screening services to enable more seamless identification and enrollment of patients on studies. Additionally, through SCRI's streamlined data delivery solutions, SCRI can ensure timely access to data to inform drug development and optimize clinical trial delivery. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit to learn more.
Yahoo
20-05-2025
- Business
- Yahoo
IQVIA and SCRI partner to enhance oncology trials
IQVIA has partnered with SCRI Development Innovations, the contract research organisation branch of the Sarah Cannon Research Institute (SCRI), aimed at transforming oncology clinical trials for biopharma collaborators worldwide. This partnership is said to improve trial processes, remove operational challenges, expedite data delivery, and enhance the availability of new therapies to individuals. It claims to use IQVIA's worldwide reach, trial management, and data integration capabilities. SCRI will contribute its community oncology knowledge and Accelero, an operational model that accelerates trial activation and improves recruitment at SCRI sites within the US. The model also claims to integrate information from electronic health records directly into electronic capture systems for clinical trials data collection within the US. This integration is expected to provide sponsors with a pathway to operationalise the treatment development for individuals. Sarah Cannon Research Institute CEO Dee Anna Smith said: 'We are enthusiastic about the impact we can make in transforming clinical trial delivery through our collaboration with IQVIA. 'Through our accelerated operations model, Accelero, SCRI can alleviate the operational burden on research sites, enhance enrolment, and expedite data delivery through our cutting-edge technology solutions.' IQVIA is a clinical research service and healthcare intelligence provider, and says that its solution portfolio is powered by IQVIA Connected Intelligence. SCRI is an oncology research organisation conducting community-based trials. IQVIA research and development solutions president Richard Staub said: 'This collaboration embodies our commitment to innovation, efficiency, and delivering superior outcomes for patients by bringing together the best of both organisations and eliminating the complexities often associated with multiple vendors.' Last June, IQVIA introduced a new trial technology platform, One Home for Sites. This platform simplifies clinical trial management by providing a single sign-on and dashboard for various tasks and systems. "IQVIA and SCRI partner to enhance oncology trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16-05-2025
- Business
- Business Wire
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients. The collaboration leverages IQVIA's global reach and precision in managing one in five oncology trials in the United States, along with its ability to seamlessly integrate data, technology and analytics. These capabilities are combined with SCRI Development Innovations' community oncology expertise, and enhanced operational model, Accelero, which expedites trial activation and enhances recruitment for SCRI sites in the United States. Additionally, the Accelero model seamlessly integrates data from the electronic health record to the electronic data capture systems for U.S. clinical trial data collection. Together, these strengths offer sponsors a more effective pathway to operationalize the development of innovative treatments for patients. 'We are excited to announce our collaboration with SCRI Development Innovations,' said Richard Staub, president of Research & Development Solutions at IQVIA. 'This collaboration embodies our commitment to innovation, efficiency and delivering of superior outcomes for patients by bringing together the best of both organizations and eliminating the complexities often associated with multiple vendors. Together we will accelerate the development of new cancer therapies and improve outcomes for patients worldwide.' 'We are enthusiastic about the impact we can make in transforming clinical trial delivery through our collaboration with IQVIA,' said Dee Anna Smith, chief executive officer at Sarah Cannon Research Institute. 'Through our accelerated operations model, Accelero, SCRI can alleviate the operational burden on research sites, enhance enrollment and expedite data delivery through our cutting-edge technology solutions. Additionally, we will leverage IQVIA's global reach, expertise and capabilities in trial design and recruitment to provide a seamless global delivery model for our partners.' The collaboration between IQVIA and SCRI Development Innovations marks a significant step forward in transforming oncology trial delivery globally. Visit IQVIA at Booth 14103 or SCRI at Booth 27022 during the American Society of Clinical Oncology (ASCO) Annual Meeting May 30 to June 3 in Chicago, Ill., to learn more about this innovative partnership to advance cancer research and improve patient outcomes. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI ®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S. Visit to learn more.
